Thu-05-10-2017, 09:08 AM
A small pilot study of a wearable device by Thync Global on psoriasis patients has encouraged them to to generate clinical data through collaborations with leading institutions.
Source: fiercebiotech.com
Quote:
Thync Global, which markets wearables that help users sleep better or relax, reported the first effective use of bioelectronics to treat psoriasis in a pilot study. The noninvasive therapy “significantly” reduced psoriasis symptoms and could fill a gap in psoriasis treatment.
The pilot study involved 28 patients; 18 were treated with Thync’s device, while the remaining 10 received a placebo device. The patients used the device 10 minutes a day for four weeks.
Of the 18 patients in the treatment group, 15 (83%) reported at least a 50% reduction in redness, scaling and itchiness, compared to two patients in the control group, the company said. One-third of the treated patients reported at least a 75% reduction in symptoms, compared to none in the control group, said Sumon Pal, Thync chief scientific officer.
Worn on the neck, Thync’s device uses proprietary algorithms to deliver electrical stimulation to targeted nerves in the cervical and thoracic spine, the company said in a statement. It exploits the link between the sympathetic nervous system and the immune response.
“The nervous system plays a powerful role in modulating the immune response,” Pal said in the statement. “By creating a technology that can noninvasively manipulate the neurogenic pathways that regulate the immune system, we can provide a drug and side-effect free therapy for psoriasis.”
Source: fiercebiotech.com